Fennec Pharmaceuticals Inc (NASDAQ:FENC) has been given an average recommendation of “Buy” by the six brokerages that are currently covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and four have given a buy rating to the company. The average 1 year price target among brokerages that have covered the stock in the last year is $17.00.

A number of analysts recently weighed in on FENC shares. HC Wainwright set a $18.00 price objective on shares of Fennec Pharmaceuticals and gave the stock a “buy” rating in a research report on Tuesday, August 7th. Zacks Investment Research lowered shares of Fennec Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday, August 15th. ValuEngine lowered shares of Fennec Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, September 11th. Wedbush reduced their target price on shares of Fennec Pharmaceuticals from $17.00 to $16.00 and set an “outperform” rating on the stock in a research report on Monday, September 17th. Finally, Dawson James assumed coverage on shares of Fennec Pharmaceuticals in a research report on Thursday, October 11th. They set a “buy” rating on the stock.

Fennec Pharmaceuticals stock traded down $0.11 during midday trading on Friday, reaching $6.69. The stock had a trading volume of 38,993 shares, compared to its average volume of 49,201. Fennec Pharmaceuticals has a 52-week low of $5.94 and a 52-week high of $14.99. The firm has a market capitalization of $132.18 million, a P/E ratio of -14.23 and a beta of -0.44.

Fennec Pharmaceuticals (NASDAQ:FENC) last posted its quarterly earnings data on Tuesday, November 13th. The company reported ($0.14) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.15) by $0.01. On average, equities analysts predict that Fennec Pharmaceuticals will post -0.52 EPS for the current year.

Several large investors have recently modified their holdings of the company. United Services Automobile Association increased its position in shares of Fennec Pharmaceuticals by 20.7% during the second quarter. United Services Automobile Association now owns 55,348 shares of the company’s stock worth $578,000 after acquiring an additional 9,500 shares during the period. Granahan Investment Management Inc. MA increased its position in shares of Fennec Pharmaceuticals by 20.3% during the second quarter. Granahan Investment Management Inc. MA now owns 57,002 shares of the company’s stock worth $595,000 after acquiring an additional 9,626 shares during the period. Creative Planning purchased a new position in shares of Fennec Pharmaceuticals during the second quarter worth approximately $105,000. Bronfman E.L. Rothschild L.P. purchased a new position in shares of Fennec Pharmaceuticals during the second quarter worth approximately $151,000. Finally, Schwab Charles Investment Management Inc. purchased a new position in shares of Fennec Pharmaceuticals during the second quarter worth approximately $221,000. 47.83% of the stock is currently owned by institutional investors and hedge funds.

Fennec Pharmaceuticals Company Profile

Fennec Pharmaceuticals Inc, a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children.

Featured Article: Why do company’s buyback their stock?

Receive News & Ratings for Fennec Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fennec Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.